Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Supplemental Table 1. Summary of study information included in the analysis Colorectal cancer Gastric cancer Cance r type Author Year(Ref.) Countr y Canc er sub type Samp le type Conc Chan ge Chen 2014,(1) China GC Plasma Fu 2014,(2) Tsujiura 2014,(3) Zhu 2014,(4) Peng 2014,(5) Kim 2013,(6) Li 2013,(7) Gorur 2013,(8) Shiotani 2013,(9) Cai 2013(10) Xu 2013,(11) Li 2013,(12) Zhang 2012,(13) Wang 2012,(14) Zhou 2012, (15) China Japan China China Korea China Turkey Japan China China China China China China GC GC GC GC GC GC GC GC GC GC GC GC GC GC Plasma Plasma Plasma Serum Serum Plasma Plasma Serum Plasma Serum Plasma Serum Serum PB Down Up Up Up Up Up Up Up Down Up Up Down Up Down Up Up Liu 2012,(16) China GC Serum Up Valladares 2012,(17) Konishi 2012,(18) Spain Japan GC GC Blood Plasma Li 2012,(19) China GC Plasma Up Up Up Down Song 2012,(20) China GC Serum Up Zheng 2011,(21) Liu 2011,(22) Zhou 2010,(23) China China China GC GC GC PB Serum PB Tsujiura 2010,(24) Japan GC Plasma Toiyama 2014,(25) Japan CRC Serum Wang 2014,(26) China CRC Serum Du 2014,(27) Zanutto 2014,(28) China Italy CRC CRC Plasma Plasma Up Up Up Up Down Up Up Down Up Up Ogata 2014,(29) Japan CRC Serum Up Studied microRNAs miR-122 miR-192 miR-222 miR-18a miR-16, -25, -92a, -451, -486-5p miR-425, -191 miR-106b, -223 miR-199a-3p miR-195-5p miR-106b, -21, let-7d miR-221, -106b, -20a miR-320a miR-151-5p, -199a-3p miR-375 miR-21 miR-421 miR-320c, -1182, -150*, -936, -923, -557 miR-187*, -371-5p, -378 miR-200c miR-451, -486 miR-223, -21 miR-218 miR-221, -744, -376c, -27a, -27b, -222, -191, let-7e miR-21 miR-1, -20a, -27a, -34, -423 miR-17, -106a miR-17-5p, -21, -106a, -106b let-7a miR-200c miR-21, let-7g miR-31, -92a, -181b, -203 miR-21 miR-378, -21 miR-1268, -1290, -1308, -181b, -181d, -1915, 483-5p, -638, -1224-5p Let 7a, miR-23a, -1229, -1246, -150, -21, -223 Sample (Cases /Controls) Stage (Ⅰ/Ⅱ/Ⅲ/ Ⅳ) Assay methods Age (year) (Cases /Controls) 36/36 0/0/13/23 RT-qPCR 56(48-61)/59(48-61) 114/56 104/65 88/142 57/58 31/15 80/70 20/190 64/64 90/90 94/103 180/80 20/20 30/29 40/17 17/25/34/38 66/14/15/9 88/0/0/0 NA NA 76/4/0/0 NA NA 15/20/40/15 NA 40/29/93/18 1/1/7/4 11(I-II)/19(III-IV) 8/13/4/5 NA/NA 65.6(38-94)/NA NA/NA NA/43 NA/(28-43) 56.7/58.9 63.7(44-85)/29.94(18-69) 67.9/68.4 46.2±10.6/46.1±11.9 60.2(27-80)/59.1(23-80) 58.1/58.9 60.9/NA 58(36-84) /46 65.3±9.7/NA 10-Jul 2/1/3/1 52/15 56/30 9(I-II)/12/31 NA RT-qPCR RT-qPCR TLDA/RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-PCR Microarray Microarray / RTqPCR RT-qPCR RT-qPCR 70/70 12/11/36/11 RT-qPCR 54 (30–77)/51(26–75) 68/68 NA RT-qPCR 60.4±7.5/60.3±7.5 16(I-II)/37(III-IV) 29/56/48/23 NA RT-qPCR RT-qPCR RT-PCR NA/NA 60.2 ± 10.2/60.0 ± 10.4 62.3±9.8/NA 69/30 38/13/14/4 RT-qPCR NA/NA 182/24 NA RT-qPCR 67±10.4/64±12.9 113/89 19/43/38/13 RT-qPCR 55±7.6/57±10.4 49/49 65/70 0/42/7/0 NA RT-qPCR RT-qPCR 61.1±12.7/61.7±12.6 NA/NA 88/11 20/20/36/12 Microarray 52.9±7.8/51.0±9.2 101/19 27/20/42/12 Microarray 53/20 164/127 41/27 / RT- 56.3±12.7/53.7±9.8 65.9 (42–85)/65.3(49-74) NA/NA (35-70)/(35-65) qPCR Wang 2014,(30) China CRC Plasma Up Down Down Yong 2013,(31) Malaysia CRC Blood Up miR-409-3p miR-7, -93, -345, -25, -331-3p miR-1274b, -130a*, -3122, -4267, -520a-3p, 548u, -92a-2*, -150, -342-3p miR-122, -122* -1245, -18b*, -2116*, -296-5p, 3183, -409-5p, -513a-3p, -587 77/84 NA 112/50 25/32/31/24 Spain CRC Serum Up Luo 2013,(33) Germany CRC Plasma Up Giráldez 2013,(34) Spain CRC Plasma Up Kanaan 2013,(35) USA CRC Plasma Up Greenberg 2013,(36) Israel CRC Serum Liu 2013,(37) Toiyama 2013,(38) Zhang 2013,(39) Wang 2012,(14) Wang 2012,(40) Wang 2012,(41) Kanaan 2012,(42) Nugent 2012,(43) Cheng 2011,(44) Pu,2010,(45) China Japan China China China China USA Ireland USA China CRC CRC CRC CRC CRC CRC CRC CRC CRC CRC Serum Serum Plasma Serum Serum Plasma Plasma WB Plasma Plasma Heneghan 2010,(46) Ireland CRC Plasma Huang 2010,(47) China CRC Plasma CRC Plasma Up Zhang 2014,(49) Hong Kong China HCC Serum Giray 2014,(50) Turkey HCC Plasma Chiu 2013,(51) Xie 2014,(52) Shen 2013,(53) Fu 2013,(54) HCC HCC HCC HCC Serum Serum Plasma Serum HCC Serum Up Tomimaru 2012,(56) Taiwan China USA China Hong Kong Japan Up Up Down Up Down Up Up HCC Plasma Qi 2011,(57) China HCC Serum Up Up Down Ng 2009,(48) Hepatocellular cancer Down Up Up Up Up Up Up Down Up Down Down Up Down Up Up Down Liu 2012,(55) 64/44 Microarray 64.4±9.0/61.5±9.3 30/26 0/0/30/0 Microarray PCR RT-qPCR 80/114 22/25/26/5 RT-qPCR 68.0±10.4/62.5±7.5 42/53 8/13/16/5 RT-qPCR 62.8/62.1 45/26 3/12/15/15 RT-qPCR 61.2(31-86)/60(29-85) 20/20 NA RT-qPCR 55.5(24-70)/NA 200/80 186/53 78/86 32/29 114/0 90/58 30/30 63/45 74/28 103/37 18/96/64/22 45/57/43/41 36(I-II)/42(III-IV) 19(I-II)/13(III-IV) 0/27/70/20 26/25/29/10 3/4/15/4 5/22/19/16 8/14/17/35 7/38/40/18 RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR Microfluidic array RT-qPCR RT-qPCR RT-qPCR 57.9 (20-89)/57.5(28-89) 67.5/64 61.4/60.3 63(45-80)/46 28-82 61(21-84)/56(36-85) 60(43-76)/60(42-78) 71.2(35-90)/53.4(27-89) 54.2/55.3 58(39-84)/32(17-77) 30/63 7/13/9/1 RT-qPCR 68.8(45-88)/52.1(24-80) 100/59 27/25/38/10 RT-qPCR 61(26–84)/56(27–81) miR-17-3p, -92 130/75 6/35/39/50 RT-qPCR 71(42–91)/69(45–85) miR-143, -215 miR-125b-5p, -92a-3p, -122-5p miR-223-3p miR-130b miR-101 miR-483-5p miR-101 95/127 37/29/16/3 RT-qPCR 54.21±6.95/52.58±6.98 20/28 NA RT-qPCR 60.4±2.57/49.58±2.002 20-Jun 67/30 49/49 25/20 NA 42/6/19(III-IV) 19(I-II)/30(III-IV) 6/14/5/0 RT-qPCR RT-qPCR RT-qPCR RT-qPCR NA/NA 51.69/37.26 61.1±11.7/61.5±11.0 NA/NA miR-15b, -130b, -21, -183 57/59 45(I-II)/11(III-IV) RT-qPCR NA/NA miR-21 miR-122, -222, -223 miR-21 126/50 67/16/43/0 RT-qPCR 63±10/62±8 70/34 8/36/20/6 RT-qPCR 49/38 miR-338-5p, -23b, -483-3p, -193a-3p, -23a Brunet 2013,(32) RT-qPCR miR-18a, -29a miR-145, -18a, -20a, -21, -29a, -92a, -106b, 133a, -143 miR-18a, -19a, -19b, -15b, -29a, -335 miR-25, -192, -431, -15b, -139-3p, -21, -331, 423-5p, -339-3p, -142-3p miR-29c miR-324-3p miR-92a, -21 miR-21 miR-200c, -18a miR-21 miR-29a miR-601, -760 miR-21 miR-34a miR-92 miR-221 miR-10b, -145, -155 let-7a miR-29a, -92a miR-25 / RT68.1±11/64.1±7.4 Gui 2011,(58) Xu 2011,(59) Qu 2011,(60) China China USA HCC HCC HCC Serum Serum Serum Zhou 2011,(61) China HCC Plasma Up Up Down Up Down Down Ganepola,2014,(62) USA PCC Plasma Lung cancer Pancreatic cancer Up miR-885-5p miR-21, -122, -223 miR-195, -16, -199a miR-194, -23b, -122, -192, -21, -801 miR-26a, -27a, -223 miR-486-5p, -18b, -1288, -486-3p, -18a, -7, 26b, -646, -1295, -301a, -106b, let-7i, -16, -20b, -93, -106a, -17, -19b, -1468, -29b, -15b, -186, 10b, -143, -181a, -222, -221, -210, -21 miR-3184, -1909, -3154, -711, -3125, -4253, 762, -3188, -194, -193b Up miR-642b, -885-5p, -22 miR-196a, -196b miR-21, -483-3p miR-205, -210, -492, -1427 miR-744*, -1290, -628-3p, -550, -1825, -24, 134, -146a, -200c, -378, -484, -625, -22, -210 miR-221 miR-27a-3p, -16-5p, -15-5p miR-375, -141, -548b-5p, -513a-3p miR-222, -92a, -221 miR-20a, -21, -24, -25, -99a, -185, -191 miR-210, -16, -21, -155, -181a, -181b, -196a miR-100a, -10 miR-18a miR-200a, -200b miR-21, -210, -155, -196a Slater 2014,(63) Abue 2014,(64) Wang 2014,(30) Germany Japan USA PCC PCC PCC Serum Plasma PJ Up Up Up Li 2013,(31) USA PCC Serum Up Kawaguchi 2013,(65) Frampton 2013,(66) Japan UK PCC PCC Plasma PBMC Carlsen 2013,(67) Denmark PCC Plasma Liu R 2012,(68) Liu J 2012,(69) LaConti 2011,(70) Morimura 2011,(71) Li 2010,(72) Wang 2009,(73) China China USA Japan USA USA Serum Plasma Plasma Plasma Serum Plasma Krysan2014,(74) USA Plasma Up Shin 2014,(75) Korea PE Yu 2014,(76) China Plasma Franchina2014,(77) Italy PCC PCC PCC PCC PCC PCC NSCL C LADC NSCL C NSCL C NSCL C Up Up Up Down Up Up Up Up Up Up 46/24 101/89 105/71 NA NA NA 204/68 NA RT-qPCR RT-qPCR RT-qPCR Microarray qPCR 11-Aug NA 54.2/50.6 NA/NA 55(25-80)/NA / RT- 53/44 Microarray 64 (57-65)/46 (42-49) Microarray qPCR RT-qPCR RT-qPCR RT-qPCR Microarray PCR RT-qPCR RT-qPCR / RT- 11-Nov NA 19/10 32/30 50/19 2/7/0/10 1/8/10/13 NA 41/19 6/28/7/0 47/30 129/60 NA NA 48/47 6/21/2021 RT-qPCR 65.49/59.53 95/81 138/68 8-Jun 36/30 45/32 49/36 NA 27/39/17/55 1/5/0/0 1/20/0/8 NA NA RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-PCR RT-qPCR 62.57/58.39 61.8/60.5 68.0/50.9 68(42-84)/NA 64.4 ± 10.0/44.3 ± 10.2 NA/NA NA/(25-50) 70.6(48-89)/74.6(61-89) NA/NA / RT- 65.2±10.1/43.8±11.5 67(42-84)/NA NA/NA miR-17, -18a, -19a, -19b, -20a, -92a 30/30 NA Sequencing NA/NA Down miR-134, -185, -22 45/42 NA RT-qPCR 68 (33-92)/61 (22-92) Down miR-375 30/42/58/34 RT-qPCR 58.02±9.75/58.89±9.32 0/0/6/16 RT-qPCR 63(46-78)/NA 34(I-II)/118(III-IV) RT-qPCR NA/NA 60/35 NA RT-qPCR 69.8/66.4 40/40 10/10/10/10 RT-qPCR 65.5/64.2 WB Up Serum Down Up LC Plasma Up miR-22, -24, -34a 164/164 22/27 Yang 2014,(78) China Cazzoli 2013,(79) Italy Rani 2013,(80) Ireland LADC Serum Up Down miR-152, -148a, -148b miR-21 miR-378a, -379, -139-5p, -200b-5p, -151a-5p, 1974, -376a-5p, -30a-3p, -154-3p, -190b, -5025p, -629, -17, -100 miR-30c-1*, -616*, -146b-3p, -566, -550, -939 miR-339-5p, -656 Han,2013(81) South Korea LADC PE Down miR-198 45/42 NA Abd-ElFattah2013,(82) Egypt LC Serum Up miR-21, -155, -182, -197 65/37 NA 152/300 Microarray qPCR Microarray qPCR / RT- / RT- 68(33-92)/61(22-92) 54.1±12.8/50.1±14.2 Breast cancer Down miR-10a miR-21, -30e-5p miR-21 miR-21,-155 miR-145 miR-942, -630, -190b, -144, let-7f, -15a, -20a, 18a, -1976, -93, -20b, -320c, -17, -652, -18b miR-1284, -720, -1290 Serum Down miR-625*, -361-3p 97/30 NA RT-qPCR 65(37-84)/40(21-66) Serum Up miR-21, -205, -30d, -24 82/50 45/37(II-IV) RT-qPCR 59/NA Serum Up miR-125b 193/110 24/52/54/63 RT-qPCR NA/NA 220/220 180/40/0/0 RT-qPCR 67.5(37-88)/67.7(33-86) 200/110 60/28/82/30 RT-qPCR 59.5±10.3/58.7±8.2 Markou2013,(83) Greece Wang2012,(14) China NSCL C LC Tang,2013,(84) China LC Plasma Patnaik2012,(85) USA LADC WB Roth2012,(86) Germany Le 2012,(87) China Ma 2012,(88) China Heegaard,2012,(89) USA Chen 2012,(90) China Hennessey 2012,(91) USA Silva 2011,(92) Spain Roth 2011,(93) Zheng 2011,(94) Germany USA Wei 2011,(95) China NSCL C NSCL C NSCL C NSCL C NSCL C NSCL C NSCL C LC LC NSCL C NSCL C LC LC NSCL C NSCL C NSCL C BC Plasma Serum Serum Down Up Up Up Down Up Down Up Serum Up Serum Up Plasma Down Serum Plasma Plasma miR-146b, -221, let-7a, -155, -17-5p, -27a, 106a miR-29c miR-20a, -24, -25, -145, -152, -199a-5p, -221, 222, -223, -320 37/28 NA RT-qPCR NA/NA 31/29 4(I-II)/27(III-IV) RT-qPCR 61(47-78)/46 62/60 21/16/25/0 RT-qPCR 64.8/66 22/23 14/2/6/0 Microarray 70.6(50-85)/59.9(36-74) miR-27b, -15b 55/75 33/13/7/2 RT-qPCR 68.2(48–85)/65.7(38–85) let-7f, miR-20b, -30e-3p 78/48 NA RT-qPCR NA Up Up miR-10b, -34a, -141, -155 miR-21, -128, -183, -155, -197, -182 35/28 6-Jun NA NA RT-qPCR RT-qPCR 55(32-71)/42(21-67) NA Up miR-21 63/30 18/5/5/35 RT-qPCR 61(36-83)/57(41-75) 32/29 11/8/13(III-IV) RT-qPCR 66.2/66.5 20/10 28/19 4/4/8/4 NA RT-qPCR Microarray NA/NA NA/NA PB PB Up Down Up Up miR-21, -210 miR-486-5p miR-21 let-7d, miR-328, -93*, -675 WB Down let-7a 35/30 5/1/16/13 RT-qPCR 67(48-84)/60(37-80) Plasma Up Down miR-21, -182, -210 miR-126, -486-5p 58/29 15/15/12/16 RT-qPCR 67.8/66 Serum Up miR-1254, -574-5p 22/31 6/14/0/0 RT-qPCR 62 (52–77)/62 (39–91) Serum Up Up Down miR-24 miR-15a, -18a, -107, -425 miR-133a, -139-5p, -143, -145, -365 miR-186, -425, -454, -140-3p, let-7b, -483-5p, 155, -126, -146b-5p, -320, -191, -342-3p miR-195, -486-5p, -484, -222, -574-3p, -29a 63/21 NA RT-qPCR 58/NA 48/24 NA RT-qPCR 58/57 miR-138 83/83 25/46/12/0 miR-29a, -181a, -223, -652 44/46 15/14/8/2 Shen(a)2011,(96) China Li 2011,(97) Leidinger 2011,(98) China Germany Jeong 2011,(99) Korea Shen(b)2010,(100) USA Foss 2011,(101) USA Sochor 2014,(102) Czech Kodahl 2014,(103) Denmark BC Serum Zearo 2014,(104) Australia BC Serum Plasma Up Waters 2014,(105) Ireland BC Blood Up McDermott UK BC Blood Down 39/10 NA 98/25 TLDA TLDA / RT-qPCR Microarray / RTqPCR RT-qPCR 58±16/60±6 57.2/57.1 59.86/44.21 2014,(106) miR-454*, -222, -125b-2*, -1268, -200c, -15b*, -181a-2*, -10a, -654-3p, -139-3p, -708 miR-30a, -144, -571, -93*, -487b, -1274b, 1274a, -212, -886-3p, -145, -1290, -1308, -1382* 5-Nov NA Up miR-1280, -1260, -720 232/40 NA Down Park 2014,(107) South Korea BC WB Up Microarray NA/NA USA Germany Germany Switzerla nd BC BC BC Serum Serum Serum Up Up Up miR-148b, -133a miR-373, -21, -210 miR-101, -372, -373 50/50 127/19 168/28 50(I-II)/0/0 NA NA Microarray qPCR RT-qPCR RT-qPCR RT-qPCR BC Plasma Up miR-373, -10b 10-Oct NA RT-qPCR NA/NA Mar-Aguilar 2013,(112) Mexico BC Serum Up miR-10b, -21, -125b, -145, -155, -191, -382 61/10 13/14/34/0 RT-qPCR (40-77)/NA Cuk 2013,(113) Germany BC Plasma Up 120/60 39/55/22/2 RT-qPCR 48.6(30-77)/46.5(29-77) Chan 2013,(114) Singapor e BC Serum 32/22 NA RT-qPCR 50±13/47±6 Wang 2013,(115) Zeng 2013,(116) China China BC BC Serum Plasma 46/58 100/64 NA 45/32/10/7 48.3(30-79)/52.0 51.4(30-84)/48.9(20-72) Ng 2013,(117) Hong Kong BC Plasma 185/145 50/61/27/5 RT-qPCR RT-qPCR Microarray Microarray qPCR Si 2013,(118) China BC Serum 100/20 NA RT-qPCR NA/NA Liu 2013,(119) China BC Serum 20/10 3/10/7/0 RT-qPCR NA/NA Gao 2013,(120) Wang 2012,(14) Sun 2012,(121) Jung 2012,(122) van Schooneveld 2012,(123) Schwarzenbach 2012,(124) Wang 2012,(125) Nugent 2012,(43) China China China USA BC BC BC BC 89/55 50/29 103/55 27/28 21/28/9/31 48(I-II)/2(III-IV) 29/36/30/8 NA RT-qPCR RT-qPCR RT-qPCR RT-qPCR 56(29-80)/50(28-65) 53(28–89)/46 53 (21-79)/51 (36-78) 52(21-70)/53.5(22-71) Belgium Shen 2014,(108) Müller 2014,(109) Eichelser 2014,(110) Chen 2013,(111) / RT- NA/NA NA/NA NA/NA 59(30-85)/NA Serum Serum Serum Plasma Down Up Down Up Up Down Down Up Down Up Up Up Up Up miR-801, -127-3p, -376a, -652, -148b, -376c, 409-3p let-7i,et-7b,miR-1, -133b, -133a, -92a, -10b, 486-5p, -423-5p, -7, -20a, -185, -16, -214, l, 144, -16-2*, -320a, -93 miR-223, -338-3p miR-182 miR-30a miR-27a, -150, -191, -200c, -210 miR-16, -21, -451 miR-145 miR-92a miR-21 miR-205 miR-155 miR-21 miR-21 miR-155 miR-210, -21, -126, -29a BC Serum Down miR-411, -299-5p 75/20 19/14/22/20 RT-qPCR NA/NA Germany BC Serum Up miR-20a, -21, -214 102/53 NA RT-qPCR 60(30-82)/50(20-79) China Ireland BC BC Serum WB Up Down 56/10 19/45 0/35/21/0 1/12/4/1 RT-qPCR RT-qPCR 55(36-78)/NA 58(48-79)/53.4(27-89) Schrauder 2012,(126) Germany BC WB Up 48/57 NA Microarray 62 (34-89)/58 Guo 2012,(127) China BC Serum Down miR-125b, -155, -10b miR-34a miR-4306, -425, -1323, -335, -497, -106b, -922, -516b, -202, let-7a* miR-718, -625*, -1471, -193a-3p, -182, -1915, 564, -107, -2355, -3186-3p, -24, -3130-3p, 526a, -1469, -874 miR-181a 152/75 40/79/13/16 RT-qPCR 50.38(25-83)/48.4(22-60) Up / RT- 60(36-84)/61(40-85) Cervical cancer Prostate cancer Hu 2012,(128) Wu 2012,(129) Zhao 2012,(130) Asaga 2011,(131) Heneghan 2010,(46) Roth 2010,(132) China China China USA Ireland Germany BC BC BC BC BC BC Serum Serum Serum Serum Plasma Serum Up Up Up Up Up Up Zhao 2010,(133) USA BC Plasma Up Chen 2013,(134) China CC Serum Up Zhao 2013,(135) Yu 2012,(136) Li 2014,(137) Wang 2014,(138) Farina 2014,(139) China China China China USA CC CC CC CC PC Serum Serum Serum Serum Serum Cheng 2013,(140) USA PC Serum Up Down Down Up Up Up Down Up Up Down Up Up Nguyen 2013,(141) USA PC Serum Selth 2012,(142) Shen 2012,(143) Australia USA PC PC Serum Plasma Bryant 2012,(144) USA PC Plasma Chen 2012,(145) China PC Plasma Heneghan 2012,(46) Ireland PC Plasma Gonzales 2011,(146) Brase 2011,(147) Mitchell 2008,(148) USA USA USA PC PC PC Plasma Plasma Serum Up Down Down Up Down Up Up Up Up miR-16, -25, -222, -324-3p miR-222 miR-10b miR-21 miR-195, let-7a miR-155, -10b, -34a miR-595, -589, -504, -518b, -483-5p, -425*, 493, -187, -431*, -1231 miR-668, -377, -410, -922, -155, -340*, -432, 574-3p, -148a, -181a, -1275, -1304, -151-5p miR-1246, -20a, -2392, -3147, -3162-5p, -4484, -4667-5p miR-20a, -203 miR-218 miR-1, -2 miR-646 miR-21-5p, -93-5p miR-100, -148a, -425-5p miR-222 miR-141, -200a, -200c, -210, -375 miR-375,-378*,-141 miR-409-3p miR-375, -141, -298, -346 miR-20a, -21, -145 miR-107, -130b, -141, -2110, -301a, -326, -3313p, -432, -484, -574-3p, -625* miR-181a-2* let-7e, let-7c, -30c miR-1285, -622 miR-145, -155 let-7a miR-141 miR-375, -141 miR-141, -100, -125b, -143, -296 76/76 50/50 122/59 102/20 83/63 89/29 24/36/16/0 50(I-II) 22/48/20/22 31/26/22/23 14/35/18/6 NA RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR 52.99/49.16 55/53 52(26-77)/50(28-72) NA/NA 55.1(30-88)/52.1(24-80) 56(31-82)/NA 20/20 20(I-II) Microarray 56/57 40/20 NA RT-qPCR NA/NA 80/20 90/50 112/85 15-Oct 6-Oct 0/80(I-II/0/0) 62/18/6/4 NA 0/9/1/0/0 NA RT-qPCR RT-qPCR RT-qPCR RT-qPCR RT-qPCR 49(25-69)/45(33-57) 51.0(36-70)/NA 47.86/NA 51(34-78)/28.8(24-34) NA/NA 25/25 NA TLDA NA/NA TLDA / RT-qPCR 84/0 NR RT-qPCR 60 (53–69) 25/25 82/0 NA 0/82(Ⅱ-Ⅲ)/0 RT-qPCR RT-qPCR 73.5(45-86)/NA 61.2 78/28 NA RT-qPCR 70/63 80/54 NA RT-qPCR 73(57-94)/73(54-84) 20/63 1/10/9/0 RT-qPCR 60.6(50-68)/52.1(24-80) 21/0 137/0 25/25 NR NR NA RT-qPCR TLDA and RT-qPCR RT-qPCR 60-77 63.1 NA/NA Abbreviations: NSCLC, Non-small cell lung cancer; LADC, Lung adenocarcinoma; LC, Lung cancer; HCC, Hepatocellular cancer; GC, Gastric cancer; PCC, Pancreatic cancer; CRC, Colorectal cancer; PC, Prostate cancer; BC, Breast cancer; CC,Cervical cancer; NA, not available; PE, Pleural effusion; WB, Whole blood; PJ, Pancreatic juice; PBMC,peripheral blood mononuclear cell; PB, peripheral blood; TLDA, TaqMan low density arrays. Supplemental Figure 1. Number of patients involved in each sample type (A) and number of dysregulated miRNA identified in each cancer type (B). A) B) Supplemental References 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang Q, et al. Plasma mir-122 and mir-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncology reports 2014;31:186370. Fu Z, Qian F, Yang X, Jiang H, Chen Y, Liu S. Circulating mir-222 in plasma and its potential diagnostic and prognostic value in gastric cancer. Medical Oncology 2014;31:1-8. Tsujiura M, Komatsu S, Ichikawa D, Shiozaki A, Konishi H, Takeshita H, et al. Circulating mir-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer. Gastric Cancer 2014:1-9. Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, et al. A five-microrna panel in plasma was identified as potential biomarker for early detection of gastric cancer. British journal of cancer 2014;110:2291-9. Peng W-Z, Ma R, Wang F, Yu J, Liu Z-B. Role of mir-191/425 cluster in tumorigenesis and diagnosis of gastric cancer. International journal of molecular sciences 2014;15:4031-48. Kim SY, Jeon TY, Choi CI, Kim DH, Kim DH, Kim GH, et al. Validation of circulating mirna biomarkers for predicting lymph node metastasis in gastric cancer. The Journal of Molecular Diagnostics 2013;15:6619. Li C, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY, Zhu ZG. Mirna‐199a‐3p: A potential circulating diagnostic biomarker for early gastric cancer. Journal of surgical oncology 2013;108:89-92. Gorur A, Fidanci SB, Unal ND, Ayaz L, Akbayir S, Yaroglu HY, et al. Determination of plasma microrna for early detection of gastric cancer. Molecular biology reports 2013;40:2091-6. Shiotani A, Murao T, Kimura Y, Matsumoto H, Kamada T, Kusunoki H, et al. Identification of serum mirnas as novel non-invasive biomarkers for detection of high risk for early gastric cancer. British journal of cancer 2013;109:2323-30. Cai H, Yuan Y, Hao Y-F, Guo T-K, Wei X, Zhang Y-M. Plasma micrornas serve as novel potential biomarkers for early detection of gastric cancer. Medical Oncology 2013;30:1-7. Xu Q, Dong Q-G, Sun L-p, He C-y, Yuan Y. Expression of serum mir-20a-5p, let-7a, and mir-320a and their correlations with pepsinogen in atrophic gastritis and gastric cancer: A case–control study. BMC clinical pathology 2013;13:11. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. Microrna array analysis finds elevated serum mir-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clinical Cancer Research 2013;19:3600-10. Zhang W-H, Gui J-H, Wang C-Z, Chang Q, Xu S-P, Cai C-H, et al. The identification of mir-375 as a potential biomarker in distal gastric adenocarcinoma. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2012;20:139-47. Wang B, Zhang Q. The expression and clinical significance of circulating microrna-21 in serum of five solid tumors. Journal of cancer research and clinical oncology 2012;138:1659-66. Zhou H, Xiao B, Zhou F, Deng H, Zhang X, Lou Y, et al. Mir-421 is a functional marker of circulating tumor cells in gastric cancer patients. Biomarkers 2012;17:104-10. Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, et al. Genome-wide microrna profiles identify mir-378 as a serum biomarker for early detection of gastric cancer. Cancer letters 2012;316:196-203. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, et al. Circulating mir-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 2012;10:186. Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, et al. Detection of gastric cancerassociated micrornas on microrna microarray comparing pre-and post-operative plasma. British journal of cancer 2012;106:740-7. Li B-s, Zhao Y-l, Guo G, Li W, Zhu E-d, Luo X, et al. Plasma micrornas, mir-223, mir-21 and mir-218, as novel potential biomarkers for gastric cancer detection. PloS one 2012;7:e41629. Song M-y, Pan K-f, Su H-j, Zhang L, Ma J-l, Li J-y, et al. Identification of serum micrornas as novel noninvasive biomarkers for early detection of gastric cancer. PloS one 2012;7:e33608. Zheng Y, Cui L, Sun W, Zhou H, Yuan X, Huo M, et al. Microrna-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomarkers 2011;10:71-7. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microrna signature identified from genomewide serum microrna expression profiling serves as a fingerprint for gastric cancer diagnosis. European 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. journal of cancer 2011;47:784-91. Zhou H, Guo J-M, Lou Y-R, Zhang X-J, Zhong F-D, Jiang Z, et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microrna as a marker. Journal of molecular medicine 2010;88:709-17. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, et al. Circulating micrornas in plasma of patients with gastric cancers. British journal of cancer 2010;102:1174-9. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum mir-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Annals of surgery 2014;259:735-43. Wang J, Huang S-k, Zhao M, Yang M, Zhong J-l, Gu Y-y, et al. Identification of a circulating microrna signature for colorectal cancer detection. PloS one 2014;9:e87451. Du M, Liu S, Gu D, Wang Q, Zhu L, Kang M, et al. Clinical potential role of circulating micrornas in early diagnosis of colorectal cancer patients. Carcinogenesis 2014:bgu189. Zanutto S, Pizzamiglio S, Ghilotti M, Bertan C, Ravagnani F, Perrone F, et al. Circulating mir-378 in plasma: A reliable, haemolysis-independent biomarker for colorectal cancer. British journal of cancer 2014;110:1001-7. Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al. Circulating exosomal micrornas as biomarkers of colon cancer. PloS one 2014;9:e92921. Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X, et al. A plasma microrna panel for early detection of colorectal cancer. International Journal of Cancer 2014. Yong FL, Law CW, Wang CW. Potentiality of a triple microrna classifier: Mir-193a-3p, mir-23a and mir338-5p for early detection of colorectal cancer. BMC cancer 2013;13:280. Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, et al. Microrna expression profile in stage iii colorectal cancer: Circulating mir-18a and mir-29a as promising biomarkers. Oncology reports 2013;30:320-6. Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma micrornas for early detection of colorectal cancer. PloS one 2013;8:e62880. Giráldez MD, Lozano JJ, Ramírez G, Hijona E, Bujanda L, Castells A, Gironella M. Circulating micrornas as biomarkers of colorectal cancer: Results from a genome-wide profiling and validation study. Clinical Gastroenterology and Hepatology 2013;11:681-8. e3. Kanaan Z, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, et al. A plasma microrna panel for detection of colorectal adenomas: A step toward more precise screening for colorectal cancer. Annals of surgery 2013;258:400-8. Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, et al. A comparative analysis of total serum mirna profiles identifies novel signature that is highly indicative of metastatic melanoma: A pilot study. Biomarkers 2013;18:502-8. Liu G-H, Zhou Z-G, Chen R, Wang M-J, Li Y, Sun X-F. Serum mir-21 and mir-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumor Biology 2013;34:2175-81. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum mir-21 as a diagnostic and prognostic biomarker in colorectal cancer. Journal of the National Cancer Institute 2013;105:849-59. Zhang G-J, Zhou T, Liu Z-L, Tian H-P, Xia S-S. Plasma mir‑200c and mir‑18a as potential biomarkers for the detection of colorectal carcinoma. Molecular and clinical oncology 2013;1:379-84. Wang L-g, Gu J. Serum microrna-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer epidemiology 2012;36:e61-e7. Wang Y, Xie CL, Lu L, Fu DL, Zheng GQ. Chinese herbal medicine paratherapy for parkinson's disease: A meta-analysis of 19 randomized controlled trials. Evid Based Complement Alternat Med 2012;2012:534861. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S. Plasma mir-21: A potential diagnostic marker of colorectal cancer. Annals of surgery 2012;256:544-51. Nugent M, Miller N, Kerin M. Circulating mir‐34a levels are reduced in colorectal cancer. Journal of surgical oncology 2012;106:947-52. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma mir-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PloS one 2011;6:e17745. Pu Xx, Huang Gl, Guo Hq, Guo Cc, Li H, Ye S, et al. Circulating mir‐221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. Journal of gastroenterology and hepatology 2010;25:1674-80. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic mirna-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. The oncologist 2010;15:673-82. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma micrornas are promising novel biomarkers for early detection of colorectal cancer. International Journal of Cancer 2010;127:118-26. Ng EK, Chong WW, Lam EK, Shin VY, Yu J, Poon TC, et al. Differential expression of micrornas in plasma of colorectal cancer patients: A potential marker for colorectal cancer screening. Gut 2009. Zhang Z-q, Meng H, Wang N, Liang L-n, Liu L-n, Lu S-m, Luan Y. Serum microrna 143 and microrna 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagnostic pathology 2014;9:135. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, Sezgin O, et al. Profiles of serum micrornas; mir125b-5p and mir223-3p serve as novel biomarkers for hbv-positive hepatocellular carcinoma. Molecular biology reports 2014:1-7. Chiu L-Y, Kishnani PS, Chuang T-P, Tang C-Y, Liu C-Y, Bali D, et al. Identification of differentially expressed micrornas in human hepatocellular adenoma associated with type i glycogen storage disease: A potential utility as biomarkers. Journal of gastroenterology 2013:1-11. Xie Y, Yao Q, Butt AM, Guo J, Tian Z, Bao X, et al. Expression profiling of serum microrna-101 in hbvassociated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer biology & therapy 2014;15:1248-55. Shen J, Wang A, Wang Q, Gurvich I, Siegel AB, Remotti H, Santella RM. Exploration of genome-wide circulating microrna in hepatocellular carcinoma: Mir-483-5p as a potential biomarker. Cancer Epidemiology Biomarkers & Prevention 2013;22:2364-73. Fu Y, Wei X, Tang C, Li J, Liu R, Shen A, Wu Z. Circulating microrna‑101 as a potential biomarker for hepatitis b virus‑related hepatocellular carcinoma. Oncology letters 2013;6:1811-5. Liu AM, Yao T-J, Wang W, Wong K-F, Lee NP, Fan ST, et al. Circulating mir-15b and mir-130b in serum as potential markers for detecting hepatocellular carcinoma: A retrospective cohort study. BMJ open 2012;2. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating< i> microrna21</i> as a novel biomarker for hepatocellular carcinoma. Journal of hepatology 2012;56:167-75. Qi P, Cheng S-q, Wang H, Li N, Chen Y-f, Gao C-f. Serum micrornas as biomarkers for hepatocellular carcinoma in chinese patients with chronic hepatitis b virus infection. PloS one 2011;6:e28486. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microrna characterization identifies mir-8855p as a potential marker for detecting liver pathologies. Clinical science 2011;120:183-93. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating micrornas, mir‐21, mir‐122, and mir‐ 223, in patients with hepatocellular carcinoma or chronic hepatitis. Molecular carcinogenesis 2011;50:13642. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating micrornas as biomarkers for hepatocellular carcinoma. Journal of clinical gastroenterology 2011;45:355-60. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microrna panel to diagnose hepatitis b virus– related hepatocellular carcinoma. Journal of Clinical Oncology 2011;29:4781-8. Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A, Chang DH. Novel blood-based microrna biomarker panel for early diagnosis of pancreatic cancer. World journal of gastrointestinal oncology 2014;6:22. Slater EP, Strauch K, Rospleszcz S, Ramaswamy A, Esposito I, Klöppel G, et al. Microrna-196a and -196b as potential biomarkers for the early detection of familial pancreatic cancer. Translational Oncology 2014;7:464-71. Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K, Sato I, et al. Circulating mir-483-3p and mir21 is highly expressed in plasma of pancreatic cancer. International journal of oncology 2015;46:539-47. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, et al. Clinical impact of circulating mir-221 in plasma of patients with pancreatic cancer. British journal of cancer 2013;108:361-9. Frampton AE, Fletcher CE, Gall TM, Castellano L, Bevan CL, Stebbing J, Krell J. Circulating peripheral blood mononuclear cells exhibit altered mirna expression patterns in pancreatic cancer. Expert review of molecular diagnostics 2013;13:425-30. Carlsen AL, Joergensen MT, Knudsen S, de Muckadell OBS, Heegaard NH. Cell-free plasma microrna in pancreatic ductal adenocarcinoma and disease controls. Pancreas 2013;42:1107-13. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, et al. Serum microrna expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clinical chemistry 2012;58:610-8. Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, et al. Combination of plasma micrornas with serum ca19‐9 for early detection of pancreatic cancer. International Journal of Cancer 2012;131:683-91. LaConti JJ, Shivapurkar N, Preet A, Mays AD, Peran I, Kim SE, et al. Tissue and serum micrornas in the krasg12d transgenic animal model and in patients with pancreatic cancer. PloS one 2011;6:e20687. Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H, et al. Novel diagnostic value of circulating mir-18a in plasma of patients with pancreatic cancer. British journal of cancer 2011;105:173340. Li A, Omura N, Hong S-M, Vincent A, Walter K, Griffith M, et al. Pancreatic cancers epigenetically silence sip1 and hypomethylate and overexpress mir-200a/200b in association with elevated circulating mir-200a and mir-200b levels. Cancer research 2010;70:5226-37. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, et al. Micrornas in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer prevention research 2009;2:807-13. Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, et al. Pge2-driven expression of c-myc and oncomir-17-92 contributes to apoptosis resistance in nsclc. Molecular Cancer Research 2014;12:765-74. Shin YM, Yun J, Lee O-J, Han H-S, Lim S-N, An JY, et al. Diagnostic value of circulating extracellular mir-134, mir-185, and mir-22 levels in lung adenocarcinoma-associated malignant pleural effusion. Cancer Research and Treatment 2014;46:178-85. Yu H, Jiang L, Sun C, Guo L, Lin M, Huang J, Zhu L. Decreased circulating mir-375: A potential biomarker for patients with non-small-cell lung cancer. Gene 2014;534:60-5. Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, et al. Circulating mir‐22, mir‐24 and mir‐34a as novel predictive biomarkers to pemetrexed‐based chemotherapy in advanced non‐small cell lung cancer. Journal of cellular physiology 2014;229:97-9. Yang J-s, Li B-j, Lu H-w, Chen Y, Lu C, Zhu R-x, et al. Serum mir-152, mir-148a, mir-148b, and mir-21 as novel biomarkers in non-small cell lung cancer screening. Tumor Biology 2014:1-8. Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN, Pass HI. Micrornas derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. Journal of Thoracic Oncology 2013;8:1156-62. Rani S, Gately K, Crown J, O’Byrne K, O’Driscoll L. Global analysis of serum micrornas as potential biomarkers for lung adenocarcinoma. Cancer Biol Ther 2013;14:1104-12. Han HS, Yun J, Lim Sn, Han JH, Lee KH, Kim ST, et al. Downregulation of cell‐free mir‐198 as a diagnostic biomarker for lung adenocarcinoma ‐associated malignant pleural effusion. International Journal of Cancer 2013;133:645-52. Abd-El-Fattah AA, Sadik NAH, Shaker OG, Aboulftouh ML. Differential micrornas expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell biochemistry and biophysics 2013;67:875-84. Markou A, Sourvinou I, Vorkas P, Yousef G, Lianidou E. Clinical evaluation of microrna expression profiling in non small cell lung cancer. Lung Cancer 2013;81:388-96. Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, et al. Identification of plasma micrornas as novel noninvasive biomarkers for early detection of lung cancer. European Journal of Cancer Prevention 2013;22:540-8. Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A. Microrna expression profiles of whole blood in lung adenocarcinoma. PloS one 2012;7:e46045. Roth C, Stückrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H. Low levels of cell-free circulating mir-361-3p and mir-625* as blood-based markers for discriminating malignant from benign lung tumors. PloS one 2012;7:e38248. Le H-B, Zhu W-Y, Chen D-D, He J-Y, Huang Y-Y, Liu X-G, Zhang Y-K. Evaluation of dynamic change of serum mir-21 and mir-24 in pre-and post-operative lung carcinoma patients. Medical Oncology 2012;29:3190-7. Yuxia M, Zhennan T, Wei Z. Circulating mir-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. Journal of cancer research and clinical oncology 2012;138:2045-50. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro‐rna expression profiles in early stage nonsmall cell lung cancer. International Journal of Cancer 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 2012;130:1378-86. Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, et al. Identification of ten serum micrornas from a genome‐wide serum microrna expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. International Journal of Cancer 2012;130:1620-8. Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, et al. Serum microrna biomarkers for detection of non-small cell lung cancer. PloS one 2012;7:e32307. Silva J, García V, Zaballos A, Provencio M, Lombardía L, Almonacid L, et al. Vesicle-related micrornas in plasma of nonsmall cell lung cancer patients and correlation with survival. European Respiratory Journal 2011;37:617-23. Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Molecular oncology 2011;5:281-91. Zheng D, Haddadin S, Wang Y, Gu L-Q, Perry MC, Freter CE, Wang MX. Plasma micrornas as novel biomarkers for early detection of lung cancer. International journal of clinical and experimental pathology 2011;4:575. Wei J, Gao W, Zhu C-J, Liu Y-Q, Mei Z, Cheng T, Shu Y-Q. Identification of plasma microrna-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer. Chinese journal of cancer 2011;30:407. Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microrna biomarkers. BMC cancer 2011;11:374. Li Y, Li W, Ouyang Q, Hu S, Tang J. Detection of lung cancer with blood microrna-21 expression levels in chinese population. Oncology letters 2011;2:991. Leidinger P, Keller A, Borries A, Huwer H, Rohling M, Huebers J, et al. Specific peripheral mirna profiles for distinguishing lung cancer from copd. Lung Cancer 2011;74:41-7. Jeong HC, Kim EK, Lee JH, Yoo HN, Kim JK. Aberrant expression of let-7a mirna in the blood of nonsmall cell lung cancer patients. Molecular medicine reports 2011;4:383-7. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma micrornas as potential biomarkers for non-small-cell lung cancer. Laboratory investigation 2010;91:579-87. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. Mir-1254 and mir-574-5p: Serum-based microrna biomarkers for early-stage non-small cell lung cancer. Journal of Thoracic Oncology 2011;6:4828. Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, et al. Oncogenic micrornas: Mir-155, mir19a, mir-181b, and mir-24 enable monitoring of early breast cancer in serum. BMC cancer 2014;14:448. Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ. Novel circulating microrna signature as a potential non-invasive multi-marker test in er-positive early-stage breast cancer: A case control study. Molecular oncology 2014. Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB, Robinson BG, Soon PS. Microrna-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. BMC cancer 2014;14:200. Waters PS, Dwyer RM, Brougham C, Glynn CL, Wall D, Hyland P, et al. Impact of tumour epithelial subtype on circulating micrornas in breast cancer patients. PloS one 2014;9:e90605. McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ. Identification and validation of oncologic mirna biomarkers for luminal a-like breast cancer. PloS one 2014;9:e87032. Park IH, Kang JH, Lee KS, Nam S, Ro J, Kim J-H. Identification and clinical implications of circulating micrornas for estrogen receptor-positive breast cancer. Tumor Biology 2014;35:12173-80. Shen J, Hu Q, Schrauder M, Yan L, Wang D, Medico L, et al. Circulating mir-148b and mir-133a as biomarkers for breast cancer detection. Oncotarget 2014;5:5284. Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, et al. Changes in serum levels of mir21, mir-210, and mir-373 in her2-positive breast cancer patients undergoing neoadjuvant therapy: A translational research project within the geparquinto trial. Breast cancer research and treatment 2014;147:61-8. Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H. Increased serum levels of circulating exosomal microrna-373 in receptor-negative breast cancer patients. Oncotarget 2014;5:9650. Chen W, Cai F, Zhang B, Barekati Z, Zhong XY. The level of circulating mirna-10b and mirna-373 in detecting lymph node metastasis of breast cancer: Potential biomarkers. Tumor Biology 2013;34:455-62. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, Espino-Silva PK, Santuario-Facio SK, RuizFlores P, et al. Serum circulating microrna profiling for identification of potential breast cancer biomarkers. Disease markers 2013;34:163-9. Cuk K, Zucknick M, Madhavan D, Schott S, Golatta M, Heil J, et al. Plasma microrna panel for minimally invasive detection of breast cancer. PloS one 2013;8:e76729. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, et al. Identification of circulating microrna signatures for breast cancer detection. Clinical Cancer Research 2013;19:4477-87. Wang PY, Gong HT, Li BF, Lv CL, Wang HT, Zhou HH, et al. Higher expression of circulating mir‑182 as a novel biomarker for breast cancer. Oncology letters 2013;6:1681-6. Zeng R-c, Zhang W, Yan X-q, Ye Z-q, Chen E-d, Huang D-p, et al. Down-regulation of mirna-30a in human plasma is a novel marker for breast cancer. Medical Oncology 2013;30:1-8. Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, et al. Circulating micrornas as specific biomarkers for breast cancer detection. PloS one 2013;8:e53141. Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, Hu C. Circulating microrna-92a and microrna-21 as novel minimally invasive biomarkers for primary breast cancer. Journal of cancer research and clinical oncology 2013;139:223-9. Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of mir-205 and mir-155 expression in the blood of breast cancer patients. Chinese Journal of Cancer Research 2013;25:46. Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum mir-21 in breast cancer compared with ca153 and cea. Chinese Journal of Cancer Research 2013;25:743. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J. Serum microrna-155 as a potential biomarker to track disease in breast cancer. PloS one 2012;7:e47003. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, et al. Plasma microrna 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012;118:2603-14. van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, et al. Expression profiling of cancerous and normal breast tissues identifies micrornas that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Research 2012;14:R34. Schwarzenbach H, Milde-Langosch K, Steinbach B, Müller V, Pantel K. Diagnostic potential of ptentargeting mir-214 in the blood of breast cancer patients. Breast cancer research and treatment 2012;134:933-41. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, Luo H. Circulating mir-125b as a marker predicting chemoresistance in breast cancer. PloS one 2012;7:e34210. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, et al. Circulating micro-rnas as potential blood-based markers for early stage breast cancer detection. PloS one 2012;7:e29770. Guo L-J, Zhang Q-Y. Decreased serum mir-181a is a potential new tool for breast cancer screening. Int J Mol Med 2012;30:680-6. Hu Z, Dong J, Wang L-E, Ma H, Liu J, Zhao Y, et al. Serum microrna profiling and breast cancer risk: The use of mir-484/191 as endogenous controls. Carcinogenesis 2012:bgs030. Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide micrornas for breast cancer detection. Clinica chimica acta 2012;413:1058-65. Zhao F, Hu G, Wang X, Zhang X, Zhang Y, Yu Z. Serum overexpression of microrna-10b in patients with bone metastatic primary breast cancer. Journal of International Medical Research 2012;40:859-66. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microrna-21 concentrations in early and advanced breast cancer. Clinical chemistry 2011;57:84-91. Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H. Circulating micrornas as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research 2010;12:R90. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating mirnas as potential biomarkers of early stage breast cancer. PloS one 2010;5:e13735. Chen J, Yao D, Li Y, Chen H, He C, Ding N, et al. Serum microrna expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. International journal of molecular medicine 2013;32:557-67. Zhao S, Yao D, Chen J, Ding N. Circulating mirna-20a and mirna-203 for screening lymph node metastasis in early stage cervical cancer. Genetic testing and molecular biomarkers 2013;17:631-6. Yu J, Wang Y, Dong R, Huang X, Ding S, Qiu H. Circulating microrna-218 was reduced in cervical cancer 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. and correlated with tumor invasion. Journal of cancer research and clinical oncology 2012;138:671-4. Juan L, Tong H-l, Zhang P, Guo G, Wang Z, Wen X, et al. Identification and characterization of novel serum microrna candidates from deep sequencing in cervical cancer patients. Scientific reports 2014;4. Wang W-T, Zhao Y-N, Yan J-X, Weng M-Y, Wang Y, Chen Y-Q, Hong S-J. Differentially expressed micrornas in the serum of cervical squamous cell carcinoma patients before and after surgery. Journal of hematology & oncology 2014;7:6. Farina NH, Wood ME, Perrapato SD, Francklyn CS, Stein GS, Stein JL, Lian JB. Standardizing analysis of circulating microrna: Clinical and biological relevance. Journal of cellular biochemistry 2014;115:805-11. Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, et al. Circulating microrna profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PloS one 2013;8:e69239. Nguyen HCN, Xie W, Yang M, Hsieh CL, Drouin S, Lee GSM, Kantoff PW. Expression differences of circulating micrornas in metastatic castration resistant prostate cancer and low‐risk, localized prostate cancer. The Prostate 2013;73:346-54. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, et al. Discovery of circulating micrornas associated with human prostate cancer using a mouse model of disease. International Journal of Cancer 2012;131:652-61. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, Santella RM. Dysregulation of circulating micrornas and prediction of aggressive prostate cancer. The Prostate 2012;72:1469-77. Bryant R, Pawlowski T, Catto J, Marsden G, Vessella R, Rhees B, et al. Changes in circulating microrna levels associated with prostate cancer. British journal of cancer 2012;106:768-74. Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, Yang J. A panel of five circulating micrornas as potential biomarkers for prostate cancer. The Prostate 2012;72:1443-52. Gonzales JC, Fink LM, Goodman Jr OB, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating microrna 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clinical genitourinary cancer 2011;9:39-45. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating mirnas are correlated with tumor progression in prostate cancer. International Journal of Cancer 2011;128:608-16. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating micrornas as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences 2008;105:10513-8.